Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice

Aaron Tward ¹, Yu-Rong Xia , Xu-Ping Wang

⁰Department of Medicine, University of California, Los Angeles 90095-1679, USA.

Circulation +

|

July 24, 2002

View abstract on PubMed

Summary

Serum paraoxonase (PON1) protects against atherosclerosis. Increased PON1 levels in transgenic mice significantly reduced atherosclerotic lesions and LDL oxidation, suggesting its therapeutic potential for cardiovascular disease.

Area Of Science

Biochemistry
Cardiovascular Science
Genetics

Background

Serum paraoxonase (PON1) is an HDL-associated enzyme that inhibits LDL oxidation.
Low PON1 activity is linked to atherosclerosis in human studies.
PON1 knockout mice exhibit increased susceptibility to lipoprotein oxidation and atherosclerosis.

Purpose Of The Study

To investigate the protective role of PON1 against atherosclerosis and lipid oxidation.
To determine if PON1 confers protection in a dose-dependent manner.

Main Methods

Generation of human PON1 transgenic mice using bacterial artificial chromosome genomic clones.
Assessment of plasma PON1 and cholesterol levels.
Evaluation of atherosclerotic lesion development in dietary and apoE-null mouse models.
Testing the efficacy of HDL from transgenic mice in preventing LDL oxidation.

Main Results

Transgenic mice exhibited 2- to 4-fold higher plasma PON1 levels without changes in plasma cholesterol.
Significant reduction in atherosclerotic lesions was observed in both dietary and apoE-null models.
HDL isolated from PON1 transgenic mice demonstrated enhanced protection against LDL oxidation.

Conclusions

PON1 effectively protects against atherosclerosis in a dose-dependent manner.
These findings highlight PON1 as a potential therapeutic target for cardiovascular disease treatment.

Related Concept Videos